Fig. 3: HM phenotype in patients with P/LP germline CHEK2 variants tested for solid tumor cancer risk.
From: Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants
Characteristics of patients tested for solid tumor risk indications at the University of Utah who have the CHEK2 p.I157T variant. A Personal history of cancer for those with the CHEK2 p.I157T allele. B Primary malignancy type for those with the CHEK2 p.I157T allele who were diagnosed with cancer. C Family HM history for those with the CHEK2 p.I157T allele. D Type of HM within the family for those with the CHEK2 p.I157T allele. E–G Representative pedigrees of patients with the germline CHEK2 p.I157T allele from the University of Utah cohort. The proband is indicated by the triangle. The germline CHEK2 variant is indicated for those family members who were genotyped. Cancer diagnoses are given below each pedigree member along with the age at diagnosis (dx.) or deceased (dc.) when known. Circles indicate women, and squares, men. The generation number is given to the left in Roman numerals.
